VEGF Receptor 3 Monoclonal Antibody (AFL4), Biotin, eBioscience™, Invitrogen™

Description

• Description: The AFL4 monoclonal antibody reacts with the mouse VEGF receptor-3, also known as Flt-4
• This 195 kDa molecule was identified as an endothelial-specific member of the receptor tyrosine kinase (RTK) family
• During early embryogenesis all endothelial cells express VEGFR-3, while in the adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium
• However, VEGFR-3 expression is induced in the adult tissue upon tumor implementation suggesting an important role for this receptor in the tumor angiogenesis
• VEGF-C and VEGF-D bind to and activate VEGFR-3
• AFL4 is an antagonist mAb
• Applications Reported: The AFL4 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The AFL4 antibody has been tested by flow cytometric analysis of in vitro differentiated mouse endothelial cells
• In brief, mouse ES cells were incubated on collagen IV matrix for 4 days and subsequently stimulated with VEGF under serum free conditions to induce further differentiation
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Filtration: 0
• Vascular endothelial growth factor is a key regulator of blood vessel development in embryos and angiogenesis in adult tissues
• Unlike VEGF, the related VEGFC stimulates the growth of lymphatic vessels through its specificl ymphatic endothelial receptor VEGFR-3
• In 1998, Dumont showed that targeted inactivation of the VEGFR-3 gene in mice resulted in defective blood vessel development in early embryos
• Vasculogenesis and angiogenesis occurred, but large vessels became abnormally organized with defective lumens, leading to fluid accumulation in the pericardial cavity and cardiovascular failure at embryonic day 9.5
• Thus, VEGFR3 has an essential role in the development of theembryonic cardiovascular system before the emergence of the lymphatic vessels.